Posted on

Tacrolimus After Lung Transplant Cuts Chronic Lung Allograft Dysfunction

Loading

— Calcineurin inhibitor significantly reduced CLAD rates in Scandinavian trial

By Elizabeth Short

MILAN — Once-a-day tacrolimus significantly reduced chronic lung allograft dysfunction (CLAD) in lung transplant patients compared with the standard immunosuppressant, according to the ScanCLAD trial.

Among patients who underwent double lung transplantation, CLAD occurred significantly more often among those who received cyclosporine (cumulative incidence 39%, 95% CI 31-48) versus those who got tacrolimus (13%, 95% CI 8-21, P<0.0001) at 36 months post-procedure, reported Göran Dellgren, MD, PhD, of the University of Gothenburg, in Sweden, at the European Respiratory Societyopens in a new tab or window meeting. Read the article in MedPage Today.

Loading
Posted on

World-first Skin Cancer Treatment Aims to Help Transplant Patients

Loading

“The world-first treatment being developed at The University of Queensland is the only drug of its type that could prevent the incidence of skin cancers for transplant patients.

Lead researcher from UQ’s Diamantina Institute Dr. James Wells said the treatment was shown in models to clear skin tumors that grow as a consequence of taking tacrolimus—a drug that transplant patients must take to suppress their immune systems to avoid organ rejection.”

Read the full article, here.

Loading